Literature DB >> 29199461

Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.

Jennifer L Wilson1, Russ B Altman1,2.   

Abstract

Biomarkers are the pillars of precision medicine and are delivering on expectations of molecular, quantitative health. These features have made clinical decisions more precise and personalized, but require a high bar for validation. Biomarkers have improved health outcomes in a few areas such as cancer, pharmacogenetics, and safety. Burgeoning big data research infrastructure, the internet of things, and increased patient participation will accelerate discovery in the many areas that have not yet realized the full potential of biomarkers for precision health. Here we review themes of biomarker discovery, current implementations of biomarkers for precision health, and future opportunities and challenges for biomarker discovery. Impact statement Precision medicine evolved because of the understanding that human disease is molecularly driven and is highly variable across patients. This understanding has made biomarkers, a diverse class of biological measurements, more relevant for disease diagnosis, monitoring, and selection of treatment strategy. Biomarkers' impact on precision medicine can be seen in cancer, pharmacogenomics, and safety. The successes in these cases suggest many more applications for biomarkers and a greater impact for precision medicine across the spectrum of human disease. The authors assess the status of biomarker-guided medical practice by analyzing themes for biomarker discovery, reviewing the impact of these markers in the clinic, and highlight future and ongoing challenges for biomarker discovery. This work is timely and relevant, as the molecular, quantitative approach of precision medicine is spreading to many disease indications.

Entities:  

Keywords:  Biomarkers; drug discovery; mechanisms; molecular; precision medicine; therapeutics

Mesh:

Substances:

Year:  2017        PMID: 29199461      PMCID: PMC5813871          DOI: 10.1177/1535370217744775

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  95 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?

Authors:  Francis J McMahon
Journal:  Am J Psychiatry       Date:  2015-08-01       Impact factor: 18.112

3.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.

Authors:  Timothy A Chan; Jedd D Wolchok; Alexandra Snyder
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

4.  NCI-MATCH launch highlights new trial design in precision-medicine era.

Authors:  Caroline McNeil
Journal:  J Natl Cancer Inst       Date:  2015-07-03       Impact factor: 13.506

5.  Paying for personalized care: cancer biomarkers and comparative effectiveness.

Authors:  Rahber Thariani; David L Veenstra; Josh J Carlson; Louis P Garrison; Scott Ramsey
Journal:  Mol Oncol       Date:  2012-03-06       Impact factor: 6.603

6.  Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Authors:  Antonella Muraro; Robert F Lemanske; Peter W Hellings; Cezmi A Akdis; Thomas Bieber; Thomas B Casale; Marek Jutel; Peck Y Ong; Lars K Poulsen; Peter Schmid-Grendelmeier; Hans-Uwe Simon; Sven F Seys; Ioana Agache
Journal:  J Allergy Clin Immunol       Date:  2016-05       Impact factor: 10.793

7.  HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.

Authors:  Chun-Fang Xu; Toby Johnson; Xiaojing Wang; Chris Carpenter; Alan P Graves; Liling Warren; Zhengyu Xue; Karen S King; Dana J Fraser; Sandy Stinnett; Linda P Briley; Ionel Mitrica; Colin F Spraggs; Matthew R Nelson; Hiroomi Tada; Andreas du Bois; Thomas Powles; Neil Kaplowitz; Lini N Pandite
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

8.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

Review 9.  Precision medicine: from pharmacogenomics to pharmacoproteomics.

Authors:  Allison B Chambliss; Daniel W Chan
Journal:  Clin Proteomics       Date:  2016-09-26       Impact factor: 3.988

10.  Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants.

Authors:  Uduakobong E Ntuk; Jason M R Gill; Daniel F Mackay; Naveed Sattar; Jill P Pell
Journal:  Diabetes Care       Date:  2014-06-29       Impact factor: 19.112

View more
  3 in total

1.  S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.

Authors:  Xi-Hua Dong; Di Dai; Zhi-Dong Yang; Xiao-Ou Yu; Hua Li; Hui Kang
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

Review 2.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

3.  Meta-Analysis Reveals Both the Promises and the Challenges of Clinical Metabolomics.

Authors:  Heidi E Roth; Robert Powers
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.